GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » Price-to-Tangible-Book

Aduro Biotech (Aduro Biotech) Price-to-Tangible-Book : 12.01 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech Price-to-Tangible-Book?

As of today (2024-04-25), Aduro Biotech's share price is $14.60. Aduro Biotech's Tangible Book per Share of Jun. 2020 for the quarter that ended in Jun. 2020 was $1.22. Hence, Aduro Biotech's Price to Tangible Book Ratio of today is 12.01.

The historical rank and industry rank for Aduro Biotech's Price-to-Tangible-Book or its related term are showing as below:

ADRO's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.67
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Aduro Biotech's share price is $14.60. Aduro Biotech's Book Value per Sharefor the quarter that ended in Jun. 2020 was $2.88. Hence, Aduro Biotech's P/B Ratio of today is 5.08.


Aduro Biotech Price-to-Tangible-Book Historical Data

The historical data trend for Aduro Biotech's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech Price-to-Tangible-Book Chart

Aduro Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Tangible-Book
Get a 7-Day Free Trial 8.00 4.04 2.95 2.06 2.48

Aduro Biotech Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.81 1.54 2.48 6.69 9.50

Competitive Comparison of Aduro Biotech's Price-to-Tangible-Book

For the Biotechnology subindustry, Aduro Biotech's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aduro Biotech's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aduro Biotech's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aduro Biotech's Price-to-Tangible-Book falls into.



Aduro Biotech Price-to-Tangible-Book Calculation

Aduro Biotech's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2020 )
=14.60/1.216
=12.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Aduro Biotech Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Aduro Biotech (Aduro Biotech) Business Description

Traded in Other Exchanges
N/A
Address
740 Heinz Avenue, Berkeley, CA, USA, 94710
Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.
Executives
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman director C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat director C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich officer: Chief Business Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier director, officer: President, CEO C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King officer: Head of Renal Discovery C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich officer: Chief Medical Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber officer: SVP, GC and Secretary C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman officer: Chief Legal Officer C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710

Aduro Biotech (Aduro Biotech) Headlines

From GuruFocus

Aduro Biotech Announces Corporate Restructuring

By Marketwired Marketwired 01-10-2020